Published in PLoS One on September 03, 2015
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics (2011) 16.75
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A (2004) 4.95
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A (2010) 3.41
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A (2010) 3.03
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A (2000) 2.47
ROC analysis. AJR Am J Roentgenol (2005) 2.45
In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) (2009) 2.30
Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology (2001) 2.24
Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) (2009) 1.78
Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie (2005) 1.76
Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci (2011) 1.60
Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed (2009) 1.51
Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res (2012) 1.50
The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain. Magn Reson Imaging (2008) 1.33
Molecular body imaging: MR imaging, CT, and US. part I. principles. Radiology (2012) 1.33
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget (2014) 1.28
MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis (2000) 1.26
Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging (2007) 1.18
Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn Reson Med (2008) 1.07
Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol Cancer Ther (2014) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. Surg Oncol (2012) 0.90
Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett (2013) 0.86
Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent. Transl Oncol (2013) 0.86
In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. Cancer Res (2011) 0.85
Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma. Cancer Res (2011) 0.85
Optimizing 1.5-Tesla and 3-Tesla dynamic contrast-enhanced magnetic resonance imaging of the breasts. Magn Reson Imaging Clin N Am (2010) 0.79